Drug Use Investigation Of Bosutinib For Cml (Post Marketing Commitment Plan)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms BLF
- Sponsors Pfizer
- 22 Mar 2017 Planned End Date changed from 1 Sep 2023 to 22 Sep 2023.
- 22 Mar 2017 Planned primary completion date changed from 1 Sep 2023 to 22 Sep 2023.
- 20 Mar 2017 Planned number of patients changed from 659 to 1.